NEW YORK (GenomeWeb) — Transgenomic said after the close of the market on Wednesday that its second quarter revenues declined 7 percent year over year.

For the three months ended June 30, the Omaha, Neb.-based company reported $6.8 million in revenues compared to $7.3 million in the same quarter last year. Transgenomic said this decline was attributable to a $300,000 decrease in its Genetic Assays and Platforms segment due to fewer instrument sales, and a $200,000 drop in Laboratory Services revenues due to lower sales of contract development services to pharmaceutical clients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.